Among the topics Lu Rahman will be discussing with Wylie will be the key challenges scientists face with biomarker and drug discovery and how high-throughput screening can help alleviate this. High throughput with multiplex is valuable for drug discovery and Wylie will provide insight on this as well offering expert opinion on the future of multiplex immunoassays in drug and biomarker discovery. Tune in to hear what critical factors Wylie believes researchers should consider when choosing an assay for high-throughput screening, as well as to gain a greater understanding robustness and assay reproducibility. Wylie both outlines the challenges in this field of drug discovery and suggests ways in which these challenges can be overcome. Listen now.

Drug Discovery World - Pharma, Drug Development, Therapeutics, Chemistry & Medicine

Enhancing the role of multiplexing in high-throughput screening

Bamlanivimab was the first neutralising monoclonal antibody to receive emergency use authorisation from the FDA as a treatment for mild to moderate COVID-19 on 9 November 2020, 94 days after the monoclonal antibody discovery workflow began for the molecule. This achievement, says Eli Lilly, represents the shortest timeline from discovery to public usage for a monoclonal antibody to date. In February 2021, bamlanivimab administered with etesevimab received emergency use authorisation for treatment of recently diagnosed, mild to moderate COVID-19 in patients who are high risk for progression to severe COVID-19. Jones and Bedinger talk us through the Bamlanivimab story – and how one technology enabled this therapeutic to reach clinic in eight months during the pandemic. Tune in to find out how Eli Lilly strategised and built multiple collaborations enabling this Covid-19 therapeutic to reach patients in just over eight months, plus details of Carterra’s involvement in the process.

The Bamlanivimab story - how it reached clinic in eight months

 The latest free-to-listen DDW podcast episode is titled “Recipe for success: collaboration in drug discovery”.  It covers three articles: “Why collaboration matters and how to make it a success”; “Platform biotechnologies and the art of collaboration”; and “Cell painting: a vibrant future for phenotypic drug discovery”.   In the first article, Matthew A. Clark, Chief Executive Officer, X-Chem, spoke to Lu Rahman about the company’s experience of collaboration and how it enables innovation, flexibility and problem-solving. In the second, Benedict Cross, Chief Technology Officer at Phoremost, explains that despite its competitive nature, the drug discovery sector has embraced collaboration successfully. In the third article, Dr. Alexander Schreiner, HCS Applications Leader, PerkinElmer and Dr. Martin Daffertshofer, High Content Screening Software Product Manager, PerkinElmer discuss how cell painting is being applied today in drug discovery and the current technical limitations and challenges.  

Recipe for success: collaboration in drug discovery

 This is the latest episode of the free DDW podcast: “Opportunities to improve drug discovery systems”. It covers two articles written for Volume 22, Issue 1 – Winter 2020/21 of the Drug Discovery World Magazine.   The first article is titled “Precision control of protein release to reconfigure bioprocessing and cell-based assays”, where the authors Dr J. Mark Treherne, Dr Christian Pernstich and Dr Michael Jones examine how the controlled release of proteins will improve the reproducibility of cell-based drug discovery screens.  The second is called “Boosting pharmaceutical research with microbiome data”, where Anthony Finbow, CEO of Eagle Genomics, reports how microbiome-based evidence is set to drive understanding of how drugs interact with human ‘host’ environments, helping devise more targeted treatments and create business opportunities.  

Opportunities to improve drug discovery systems

 This is the latest episode of the free DDW podcast, “Putting virology back on the map: the fight against Covid-19”. It covers two articles written for Volume 22, Issue 1 – Winter 2020/21 of the Drug Discovery World Magazine.   The first article is a case study titled “New technology in COVID research may accelerate vaccines”, and the second is called “Virus in a well – microplate-based assays for virology research”.  The first covers the technological advancements required to understand the behaviour of the Covid molecule to develop vaccines that will prevent the virus, and arrive at a treatment we can be confident will have the highest level of effectiveness. The second answers fundamental questions: How does a virus enter host cells? How does disease develop? How can hosts be protected? How can symptoms be relieved?  

Putting virology back on the map: the fight against Covid-19

John Couse, Vice President of Scientific Services at Taconic Biosciences discusses the benefits of a robust colony management solution/partner in the drug discovery success; how it can enable companies to scale through resource management and create efficiencies. Couse has extensive knowledge of colony managements solutions and outlines the benefits they create for drug discovery researchers in terms of boosting efficiencies and achieving savings. He discusses barriers to uptake and how they can be overcome, as well as how he sees future development of these solutions.

The benefits of robust colony management in drug discovery

In this podcast Dr. Joanna Hawryluk discusses automating the cell culture workflow and explains the importance of cell culture workflow in the drug discovery process and how it can be improved thanks to technological advances. Hawryluk talks us through the cell culture workflow and its relevance within the drug discovery process focussing on the areas that hold particular importance for this process. She also shares her expertise on how important sample preparation is for downstream experimental successoffering insight into ways to improve and standardise the cell culture workflow.

Automating the cell culture workflow

This episode covers two narrated articles written for DDW and is read aloud by Megan Thomas, both of which were published in Volume 22, Issue 1 – Winter 2020/21 of Drug Discovery World. The first article is titled, “Streamlining gene therapy manufacturing will help products reach more patients”, and was written by Akash Bhattacharya, the Senior Application Scientist at Beckman Coulter Life Sciences. The second article is titled, “It’s all in the technique: how MS provides information on virus structure and function”, which was written by Andreas Huhmer, Senior Director of Proteomics and Metabolomics at Thermo Fisher Scientific.

Streamlining gene therapy and how MS provides information on virus structure

Digital transformations are having wide-ranging and profound impacts within life sciences, creating both opportunities and challenges. One of those challenges is adopting new software systems to drive the transformations. A team from Novartis Institutes of BioMedical Research (NIBR) recognised the need to ensure a good user experience for their in vivo study support groups. The NIBR team, partnered with technology provider, RockStep Solutions (RSS), to tackle the challenge. In this article, the authors present a case study illustrating a successful collaboration that created software to support complex in vivo workflows. Furthermore, they describe the repeatable 4P process they developed to help pharmaceutical companies and vendors replicate this success.

A model for successful pharma and vendor engagement

This is the latest episode of the free DDW podcast, “Paving the way for optimum drug discovery”. It covers two narrated articles written for Volume 22, Issue 1 – Winter 2020/21 Of DDW and they are read aloud by Megan Thomas. These articles are titled: “In vitro models for assessing drug toxicity: new approaches and development” and “Accelerating assay development optimisation for drug discovery”. In the first article, Karissa Cottier, PhD Research Scientist, BioIVT, ADME-Tox, examines the ongoing development and advances to ensure drug efficacy and safety. In the second, Dr. Zack Gurard-Levin, Chief Scientific Officer, SAMDI Tech offers five challenges and solutions for optimal assay development in drug discovery.

Paving the way for optimum drug discovery

Mathur talks about Twist’s antibody expertise, drawing on the company’s experience and looking at the importance of collaboration. The company has created some successful partnerships and she explains what these look like, why they have been fruitful, and how they have enabled Twist to use its capabilities to maximum effect. Listen now to hear Mathur discuss the company philosophy, how the pandemic has affected the business, its partnership experience and what the future holds for this forward-thinking company.

Antibody engineering: the importance of collaboration and successful partnerships

Aydogdu talks us through how the accurate and quantitative analysis of product purity is a fundamental component of effective development of a biotherapeutic protein. But without consistent techniques and high-quality, reproducible results, it is difficult to precisely assess the product’s efficacy and/or safety, potentially delaying, even jeopardising, its approval. He also reveals how Bio-Techne overcame this issue for a particular customer.

Comparing SDS-PAGE with automated CE-SDS for improved quantitation, reproducibility, and faster sample turn-around time.

Mälarstig  is currently responsible for developing and applying strategies for new drug targets and precision medicine. He has extensive experience working in international academic consortia and public–private partnerships such as the SCALLOP consortium. In this podcast he outlines the role of pQTLs in the drug discovery process and the growing importance of proteogenomics. In this podcast, hear Mälarstig discuss proteogenomics, an emerging approach that aims to advance basic, translational and clinical research. He will also explain why the drug discovery sector should take an interest in it, what insights can it provide to researchers and the opportunities it is creating for drug discovery companies.

The importance of proteogenomics in drug discovery with Anders Mlarstig

The latest episode of the free DDW podcast, “Precision medicine in the era of artificial intelligence”, covers one narrated article of the same title written for DDW and read aloud by Megan Thomas. It was written by Dr Lofti Chouchane and Dr Javaid Sheikh. Dr Chouchane is a professor in the departments of genetic medicine, and microbiology and immunology at Weill Cornell Medicine-Qatar. Dr Sheikh is the Dean of Weill Cornell Medicine-Qatar. The two doctors discuss the value of biobanks, artificial intelligence and machine learning, as well as the challenges associated and what’s next for these technologies and processes.

Precision medicine in the era of artificial intelligence

The latest DDW Sitting Down With podcast features Raj Indupuri, CEO of eClinical Solutions and he talks to us about clinical trials. Listen to find out why Idupuri believes ‘data is the new fuel that will drive human progress’, the effect of Covid-19 on clinical trials and what the sector can learn from the pandemic to make it better prepared for any future similar situations.

What has the pandemic taught us about clinical trials?

Here at Drug Discovery World (DDW) we've been publishing articles written by leading experts in the Drug Discovery, Pharmaceutical, and BioPharmaceutical industries for nearly 20 years. DDW has grown as a quarterly business review of drug discovery and development. However, we realised that for some, it might be easier to listen to our content on the go, so we've created this podcast to allow you to do just that. In our journal and this podcast, we cover topics surrounding: drug discovery; drug development; business; chemistry; enabling technologies; informatics; personalised medicine; screening; therapeutics, and much more. For the podcast we have selected our most recent, relevant and popular articles, so that you can listen to all of the best content from Drug Discovery World on the go. We hope you enjoy.

hubhopper

Drug Discovery World - Pharma, Drug Development, Therapeutic...

hubhopper